Business Wire (Fri, 27-Mar 5:40 PM ET)
Enveric Biosciences Announces Registration of Five Trademarks
Business Wire (Wed, 18-Mar 8:00 AM ET)
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
Business Wire (Wed, 25-Feb 8:00 AM ET)
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
Business Wire (Thu, 19-Feb 8:00 AM ET)
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
Business Wire (Thu, 29-Jan 8:00 AM ET)
Business Wire (Wed, 28-Jan 5:00 PM ET)
Business Wire (Wed, 28-Jan 8:00 AM ET)
Enveric Biosciences Announces Patent Issuance
Business Wire (Mon, 29-Dec 8:00 AM ET)
Market Chameleon (Fri, 12-Dec 3:35 AM ET)
Market Chameleon (Wed, 10-Dec 4:52 AM ET)
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Enveric Biosciences trades on the NASDAQ stock market under the symbol ENVB.
As of March 27, 2026, ENVB stock price climbed to $1.88 with 23,575 million shares trading.
ENVB has a beta of 1.25, meaning it tends to be more sensitive to market movements. ENVB has a correlation of 0.05 to the broad based SPY ETF.
ENVB has a market cap of $2.61 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ENVB traded as high as $1,256.40 and as low as $1.82.
The top ETF exchange traded funds that ENVB belongs to (by Net Assets): PSIL.
ENVB has underperformed the market in the last year with a return of -90.2%, while the SPY ETF gained +13.1%. In the last 3 month period, ENVB fell short of the market, returning -54.3%, while SPY returned -7.9%. However, in the most recent 2 weeks ENVB has outperformed the stock market by returning -1.1%, while SPY returned -4.0%.
ENVB support price is $1.77 and resistance is $1.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENVB shares will trade within this expected range on the day.